Head and Neck Cancer Therapeutics Market to Grow with a CAGR of 7.22% until 2027
The growing prevalence of different types of head and neck cancers is expected to drive the growth of Global Head and Neck Cancer Therapeutics through 2027
According to TechSci report on, “Global
Head and Neck Cancer Therapeutics Market - By
Region, Competition Forecast & Opportunities, 2027”. Global Head and Neck
Cancer Therapeutics Market stood at USD2024.33 million in 2021 and is expected
to grow at an impressive rate of 7.22% during the forecast period. This can be
ascribed to the growth in research and development activities related to cancer
treatment and developing new treatment options. The rising incidence of various
types of cancer has led to an increase in demand for developing therapies and
drugs to treat them. This, in turn, has made many government agencies, academic
& research institutions, and biotechnology & pharmaceutical companies
focus on a new therapy or drug development. These organizations are increasing
their research & development activities related to cancer diagnostics and
therapeutics. However, there are a lot of complications and post-surgery risks
associated with various head and neck cancer surgeries. These risks or
complications include temporary or permanent loss of voice, hearing loss is
also observed in certain cases, faulty speech, among others. Also, there are a
lot of side effects associated with chemotherapy, including harm caused to the
healthy cells and cancerous cells, loss of appetite, nausea, pain, vomiting,
hair loss, tiredness, anemia, sleep problems, and others.
Browse over 224 market data Figures and
13 market data Tables spread through 358
Pages and an in-depth TOC on “Global Head and Neck Cancer Therapeutics Market”.
https://www.techsciresearch.com/report/head-and-neck-cancer-therapeutics-market/5056.html
Global Head and
Neck Cancer Therapeutics Market is segmented by type, by diagnostic methods, by
treatment type, by disease indication, by route of administration, by
therapeutic class, by end user, by region and company. Based on type, the
global head and neck cancer therapeutics market can be split into diagnostic
methods and treatment types. Diagnostic methods dominated the market with a
share of around 56.89% since Diagnostic methods form an integral part of the
development of a treatment or therapy. Hence, accurate and precise diagnosis is
required for developing the right treatment. Diagnostic Methods such as Biopsy,
Imaging, and Endoscopy not only help in the early diagnosis and detection of
cancer but are done during the treatment also in order to identify the cancer
progression stages or whether the treatment provided is helping in the
treatment and elimination of different types of head and neck cancer. Based on disease
indication, the market can be fragmented into Lip and Oral Cavity Cancer,
Laryngeal Cancer, Oropharyngeal Cancer, Nasopharyngeal Cancer, Salivary Gland
Cancer and Hypopharyngeal Cancer. The Lip and Oral Cavity Cancer is expected to dominate
the market through 2027 on account of the growing prevalence of this cancer
type. According to Globocan, 377,713 new cases of lip and oral cavity cancer
were reported in 2020 and along with this number of reported deaths caused due
to lip and oral cancer were around 177,757.
A partial list
of leading companies in the Global Head and Neck Cancer Therapeutics Market
includes :
- Eli Lilly and Company
- Bristol Myers Squibb Company
- Sanofi S.A.
- Merck & Co., Inc.
- Pfizer Inc
- AbbVie Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Fresenius Medical Care AG & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Limited
- AstraZeneca Plc.
- Astellas Pharma Inc.
- AB Science SA
- Boston Biomedical, Inc.
Download
Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5056
Customers
can also request for 10% free customization on this report.
The Asia Pacific region is expected to register the fastest growth
during the forecast period. This can be attributed to the growing prevalence of
different types of head and neck cancers in the region, especially in two of
the world’s highly populated countries, China and India.
Additionally, extensive research & development activities, ongoing
clinical trials, increasing investments, expansion of companies along with
their manufacturing sites in the region especially in countries like China,
Japan, Singapore, among others for the development of therapies and drugs for
the treatment of different types of head and neck cancers is further expected
to support the market growth in the region.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research based global management consulting
firm.
“Head and Neck Cancer Therapeutics Market- Global
Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027, Segmented By
Type (Diagnostic Methods, Treatment Type), By Diagnostic Methods (Biopsy,
Imaging, Endoscopy, Others), By Treatment Type (Surgery, Radiation Therapy,
Chemotherapy, Immunotherapy, Targeted Therapy), {By Disease Indication (Lip and
Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland
Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer), By Route of
Administration (Injectable, Oral), By
Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)}, By
End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By
Region”, has evaluated the future growth potential of Global Head
and Neck Cancer Therapeutics Market and provides statistics & information
on market size, structure and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the emerging
trends along with essential drivers, challenges, and opportunities in Global Head
and Neck Cancer Therapeutics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web:
https://www.techsciresearch.com